TY - JOUR
TI - Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis
AU - Tsirigotis, P.
AU - Chondropoulos, S.
AU - Gkirkas, K.
AU - Meletiadis, J.
AU - Dimopoulou, I.
JO - Journal of thoracic disease
PY - 2016
VL - 8
TODO - 5
SP - E312-E316
PB - Pioneer Bioscience Publishing
SN - null
TODO - 10.21037/jtd.2016.03.47
TODO - Janus kinase;  ruxolitinib;  STAT protein, Article;  clinical effectiveness;  cytokine production;  disease activity;  disease association;  drug efficacy;  drug response;  homeostasis;  human;  hyperinflammation;  hypoinflammation;  immune response;  immunomodulation;  immunosuppressive treatment;  inflammation;  molecular pathology;  nonhuman;  outcome assessment;  patient monitoring;  sepsis;  treatment failure
TODO - The immune response of the host against invading pathogens is clinically manifested as sepsis. Sepsis is a complicated process characterized by distinct phases that usually occur in a sequential manner. The initial hyper-inflammation helps in elimination of the pathogen, but potentially may lead to excessive tissue injury. Hypo-inflammation helps in restoring immune homeostasis, but may lead to significant immune suppression and death from secondary infections if not appropriately controlled. Immune-modulating intervention in sepsis should be based on a balanced control of both the hyper and the hypo-inflammatory phase. © 2016. Journal of Thoracic Disease.
ER -